logo
Scientists Found Evidence of Our Ancient Human Ancestors Underwater, Suggesting a Sunken World

Scientists Found Evidence of Our Ancient Human Ancestors Underwater, Suggesting a Sunken World

Yahoo22-05-2025

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links."
Here's what you'll learn when you read this story:
Fragments of a Homo erectus skull were among deposits of vertebrate fossils found when the Indonesian seafloor was being dredged for a construction project
This is the first time fossils of this species have been found on the seafloor between the islands of Indonesia, and further investigation found that land bridges once connected the islands.
Evidence of Homo erectus hunting bovine ancestors and extracting bone marrow was also discovered.
During the glacial period that chilled the Earth 140,000 years ago, sea levels in the Indonesian region of Sundaland were low enough for present-day islands to tower like mountain ranges with a lowland savannah stretching between them. It was an expanse of mostly dry grasslands with strips of forest edging the rivers, and animals like crocodiles, river sharks, elephants, hippos, rhinos, and carnivorous lizards flourished in the region.
Sundaland was also a paradise for early humans. Long thought to have been isolated on the island of Java, two fossil fragments of a Homo erectus skull—which surfaced with recent ocean dredging in preparation for the construction of an artificial island—revealed that this hominin species migrated and spread throughout the islands when they could still walk over bridges of land.
Homo erectus was first discovered in Java (and was known as 'Java Man' until the species was officially renamed), but sossilized remains had never before been found on the seafloor between what are now the islands of Java, Bali, Sumatra and Borneo. Now that examples have been dredged up, however, Harold Berghuis—an archaeologist from the University of Leiden in the Netherlands, who led the investigation —thinks Homo erectus took advantage of the now-drowned land, and likely settled near the riverbanks in the region.
'Under the relatively dry Middle Pleistocene climate of eastern Java, herds of herbivores and groups of hominins on the lowland plains were probably dependent on large perennial rivers, providing drinking water and terrestrial as well as aquatic food sources,' Berghuis said in a study recently published in Quaternary Environments and Humans.
These human ancestors would have had plenty to take advantage of near these ancient rivers. Trees bore fruit all year, and the ancient hominins would have been able to gather edible plants in addition to catching fish and shellfish. They may have even used mussel shells as tools—the oldest known evidence of them being used for that purpose—and engraved some of them (the most ancient human engravings have been found on shells that previously turned up in Java). The new findings show that they also hunted river turtles and terrestrial animals. Bones of river turtles and bovine ancestors showed cut marks and breakages that suggested the consumption of both meat and bone marrow.
More modern human species on the Asian mainland (such as Denisovans and Neanderthals) were already known to have hunted bovids, and while no evidence for this had been found on Java, the presence of these seafloor fossils could mean that hunting methods were transferred from one species to the other. There may have even been interbreeding. Land exposed by diminished sea levels also meant that animal species from the mainland—like the extinct Asian hippo and the endangered (but still-extant) Komodo dragon—could spread to the Indonesian islands.
Homo erectus marked a significant shift in human evolution—they were the earliest hominids to bear more of a resemblance to modern humans, with larger bodies, longer legs, and shorter arms relative to their torso. More muscle mass meant that they could walk and run faster than earlier hominins, and were likely more adept hunters. An increase in body size is also associated with an increase in brain size, and skulls tell us that their brains were over 50% larger than those of early Australopithecus species (though the human brain would eventually evolve to be 40% larger than that by the time Homo sapiens appeared).
'The late Middle Pleistocene age of the site is of great interest in terms of hominin evolution, as this period is characterized by a great morphological diversity and mobility of hominin populations in the region,' Berghuis and his team said.
When sea levels rose, the land bridges between the islands of Sundaland were submerged, but this dredging has given us an unprecedented window into the life of Homo erectus in Indonesia.
You Might Also Like
The Do's and Don'ts of Using Painter's Tape
The Best Portable BBQ Grills for Cooking Anywhere
Can a Smart Watch Prolong Your Life?

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics
Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics

Yahoo

time5 hours ago

  • Yahoo

Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics

- Ongoing Phase 2 study enrolling 102 patients in the U.S. and South Korea, with more than 50% of participants identified as Asian - Selectively inhibits collagen synthesis via PRS targeting, aiming to suppressing fibrosis progression SEOUL, June 3, 2025 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-Jae Lee) announced that it presented interim results from a global Phase 2 clinical trial of its investigational idiopathic pulmonary fibrosis (IPF) treatment candidate Bersiporocin (DWN12088) at the 2025 American Thoracic Society (ATS) International Conference, held from May 16 to 21 in San Francisco. The scientific poster was presented during the official ATS session titled "WHAT'S NEW IN ILD DIAGNOSIS, MONITORING, AND TREATMENT" on May 18, by Dr. Jinwoo Song, Professor of Pulmonology at Asan Medical Center, who also serves as the trial's global Coordinating Investigator and principal investigator. The interim analysis highlighted key baseline demographic and clinical characteristics of enrolled participants, including racial distribution and antifibrotic medication use. Approximately 70% of participants were receiving Bersiporocin in combination with approved antifibrotic therapies (nintedanib or pirfenidone), while the remaining 30% participated without any background treatment. Notably, more than half of the enrolled patients are Asian— enabling exploratory assessment of treatment responses across ethnic subgroups, in contrast to prior IPF studies which were predominantly limited to White populations. The ongoing randomized, double-blind, placebo-controlled Phase 2 study is being conducted at 30 sites in the U.S. and South Korea, targeting 102 IPF patients. Participants receive 150 mg of Bersiporocin or placebo twice daily for 24 weeks, with efficacy and safety assessed based on changes in forced vital capacity (FVC) and other clinical endpoints. As of April 2025, 80 patients (approximately 80% of target enrollment) had completed registration. Bersiporocin is a first-in-class oral antifibrotic drug candidate developed by Daewoong Pharmaceutical. It selectively inhibits Prolyl-tRNA Synthetase (PRS), a key enzyme in proline activation and collagen biosynthesis. This targeted mechanism aims to interrupt the fibrotic cascade at its origin, potentially delivering more effective disease control with fewer off-target effects—positioning Bersiporocin as a next-generation therapeutic. The drug was granted Orphan Drug Designation by both the U.S. FDA and the European Medicines Agency (EMA) in 2019, and has also received Fast Track designation from the FDA—affirming its potential as a globally significant treatment option for IPF. "This trial not only offers hope for a new treatment option, but also allows us to assess responses across a racially diverse patient population, including Asian patients," said Professor Jinwoo Song. "We look forward to providing safer and more effective treatment options for patients with IPF." Seongsoo Park, CEO of Daewoong Pharmaceutical, added, "Bersiporocin represents a breakthrough in antifibrotic therapy by targeting the root cause of fibrosis through PRS inhibition. We are committed to advancing this program to help redefine the global IPF treatment paradigm." View original content to download multimedia: SOURCE Daewoong Pharmaceutical Co., Ltd. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics
Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics

Yahoo

time5 hours ago

  • Yahoo

Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics

- Ongoing Phase 2 study enrolling 102 patients in the U.S. and South Korea, with more than 50% of participants identified as Asian - Selectively inhibits collagen synthesis via PRS targeting, aiming to suppressing fibrosis progression SEOUL, June 3, 2025 /PRNewswire/ -- Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-Jae Lee) announced that it presented interim results from a global Phase 2 clinical trial of its investigational idiopathic pulmonary fibrosis (IPF) treatment candidate Bersiporocin (DWN12088) at the 2025 American Thoracic Society (ATS) International Conference, held from May 16 to 21 in San Francisco. The scientific poster was presented during the official ATS session titled "WHAT'S NEW IN ILD DIAGNOSIS, MONITORING, AND TREATMENT" on May 18, by Dr. Jinwoo Song, Professor of Pulmonology at Asan Medical Center, who also serves as the trial's global Coordinating Investigator and principal investigator. The interim analysis highlighted key baseline demographic and clinical characteristics of enrolled participants, including racial distribution and antifibrotic medication use. Approximately 70% of participants were receiving Bersiporocin in combination with approved antifibrotic therapies (nintedanib or pirfenidone), while the remaining 30% participated without any background treatment. Notably, more than half of the enrolled patients are Asian— enabling exploratory assessment of treatment responses across ethnic subgroups, in contrast to prior IPF studies which were predominantly limited to White populations. The ongoing randomized, double-blind, placebo-controlled Phase 2 study is being conducted at 30 sites in the U.S. and South Korea, targeting 102 IPF patients. Participants receive 150 mg of Bersiporocin or placebo twice daily for 24 weeks, with efficacy and safety assessed based on changes in forced vital capacity (FVC) and other clinical endpoints. As of April 2025, 80 patients (approximately 80% of target enrollment) had completed registration. Bersiporocin is a first-in-class oral antifibrotic drug candidate developed by Daewoong Pharmaceutical. It selectively inhibits Prolyl-tRNA Synthetase (PRS), a key enzyme in proline activation and collagen biosynthesis. This targeted mechanism aims to interrupt the fibrotic cascade at its origin, potentially delivering more effective disease control with fewer off-target effects—positioning Bersiporocin as a next-generation therapeutic. The drug was granted Orphan Drug Designation by both the U.S. FDA and the European Medicines Agency (EMA) in 2019, and has also received Fast Track designation from the FDA—affirming its potential as a globally significant treatment option for IPF. "This trial not only offers hope for a new treatment option, but also allows us to assess responses across a racially diverse patient population, including Asian patients," said Professor Jinwoo Song. "We look forward to providing safer and more effective treatment options for patients with IPF." Seongsoo Park, CEO of Daewoong Pharmaceutical, added, "Bersiporocin represents a breakthrough in antifibrotic therapy by targeting the root cause of fibrosis through PRS inhibition. We are committed to advancing this program to help redefine the global IPF treatment paradigm." View original content to download multimedia: SOURCE Daewoong Pharmaceutical Co., Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Scientists launch $500 million effort to harness near-limitless energy under our feet: 'A significant step forward'
Scientists launch $500 million effort to harness near-limitless energy under our feet: 'A significant step forward'

Yahoo

time16 hours ago

  • Yahoo

Scientists launch $500 million effort to harness near-limitless energy under our feet: 'A significant step forward'

Indonesia and Japan announced the financial closing of a monumental $500 million project that will add a second unit to the Muara Laboh geothermal plant in West Sumatra, Indonesia, according to the Indonesia Business Post. Former Japanese Prime Minister Fumio Kishida, who serves as special envoy for the current prime minister, met with Indonesian President Prabowo Subianto. Together, they sealed the deal and accentuated the strength of the nations' bilateral cooperation. "This 88-megawatt geothermal project in Solok, West Sumatra, marks a concrete showcase of our commitment under the Asia Zero Emission Community," Indonesia's coordinating minister for the economy, Airlangga Hartarto, told the Indonesia Business Post. "It is a significant step forward in our energy transition efforts." Kishida created AZEC as prime minister to help decarbonize Asia with other countries in the Association of Southeast Asian Nations and create, per The Associated Press, "a new, huge decarbonization market in Asia that will attract global capital." Similar initiatives are underway in the U.S. in Colorado and Texas, among other states. Although there are some concerns about geothermal energy, on the whole, it provides many environmental and human benefits. It is a renewable resource that reduces planet-warming emissions, air pollution, and dependence on fossil fuels. The geothermal energy industry also creates jobs. According to the U.S. Bureau of Labor Statistics, "Opportunities should arise for workers in a wide variety of occupations with different education and training requirements. … As the demand for clean energy grows, jobs in geothermal energy will be a small but growing potential source of new employment opportunities." In other words, it is both financially and environmentally profitable for society to move away from dirty energy and toward newer, cleaner alternatives. One of the best ways for consumers to compound the economic and environmental benefits of initiatives like these is to transition their homes to solar power. This move can bring energy costs down to or near $0. Should we be harnessing the ocean to power our homes? Absolutely Leave it be It depends I'm not sure Click your choice to see results and speak your mind. Companies such as EnergySage can help. It provides a free service that makes it easy to compare quotes from vetted local installers and save up to $10,000 on solar installation, allowing everyday homeowners to harness the power of clean energy. Voicing gratitude for the kinship and shared vision of the two nations, Hartarto said to Antara News: "Indonesia deeply appreciates Japan's commitment to sustainable development. This progress reflects both countries' efforts to foster mutually beneficial economic cooperation and shared prosperity." Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store